S. David Grayzel's most recent trade in Q32 Bio Inc. was a trade of 10,826 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Q32 Bio Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2026 | 10,826 | 10,826 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2026 | 9,810 | 9,810 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 16,363 | 16,363 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Oct 2025 | 53,521 | 53,521 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | Grayzel S. David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 18,595 | 18,595 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 18,595 | 18,595 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | Grayzel S. David | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 18,595 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | S. David Grayzel | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 12,767 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | Grayzel David S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 2,569 | 2,569 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | S. Grayzel David | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 2,569 | 0 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Sale of securities on an exchange or to another person at price $ 28.15 per share. | 09 Apr 2024 | 11,882 | 14,502 | - | 28.1 | 334,478 | Common Stock |
| Q32 Bio Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 2,569 | 2,569 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | S. David Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 3,186 | 3,186 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 2,654 | 2,654 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 7,317 | 7,317 | - | - | Stock Option (Right to Buy) |